Insider Selling: Royalty Pharma (NASDAQ:RPRX) EVP Sells 13,684 Shares of Stock

Posted by Stanley Muller on May 15th, 2026

Royalty Pharma PLC (NASDAQ:RPRX – Get Free Report) EVP Marshall Urist sold 13,684 shares of the stock in a transaction on Thursday, May 14th. The shares were sold at an average price of $53.06, for a total transaction of $726,073.04. Following the completion of the sale, the executive vice president directly owned 31,881 shares in the company, valued at approximately $1,691,605.86. This represents a 30.03% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Royalty Pharma Trading Down 1.0%

Shares of RPRX traded down $0.55 during midday trading on Friday, hitting $52.85. The stock had a trading volume of 4,264,710 shares, compared to its average volume of 3,562,113. Royalty Pharma PLC has a 1 year low of $32.15 and a 1 year high of $53.47. The firm has a market cap of $30.43 billion, a PE ratio of 35.95, a price-to-earnings-growth ratio of 1.46 and a beta of 0.40. The company has a debt-to-equity ratio of 0.86, a current ratio of 2.66 and a quick ratio of 2.66. The stock’s 50 day moving average is $48.20 and its 200 day moving average is $43.28.

Royalty Pharma (NASDAQ:RPRX – Get Free Report) last announced its earnings results on Wednesday, May 6th. The biopharmaceutical company reported $1.30 earnings per share for the quarter, beating the consensus estimate of $1.22 by $0.08. Royalty Pharma had a net margin of 33.88% and a return on equity of 29.25%. The business had revenue of $631.00 million for the quarter, compared to the consensus estimate of $881.69 million. As a group, analysts forecast that Royalty Pharma PLC will post 5.05 EPS for the current fiscal year.

Royalty Pharma Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be paid a $0.235 dividend. This represents a $0.94 annualized dividend and a yield of 1.8%. The ex-dividend date of this dividend is Friday, May 15th. Royalty Pharma’s dividend payout ratio (DPR) is currently 63.95%.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. UBS Group raised their price target on shares of Royalty Pharma from $51.00 to $57.00 and gave the stock a “buy” rating in a research note on Tuesday, April 21st. Citigroup raised their price target on shares of Royalty Pharma from $50.00 to $66.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Wall Street Zen raised shares of Royalty Pharma from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. JPMorgan Chase & Co. raised their price target on shares of Royalty Pharma from $50.00 to $58.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th. Finally, Weiss Ratings raised shares of Royalty Pharma from a “buy (b-)” rating to a “buy (b)” rating in a research note on Friday, May 1st. Seven analysts have rated the stock with a Buy rating, According to data from MarketBeat, Royalty Pharma presently has an average rating of “Buy” and a consensus price target of $53.71.

Get Our Latest Stock Report on Royalty Pharma

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. LM Advisors LLC purchased a new position in Royalty Pharma during the 4th quarter valued at about $26,000. Blue Trust Inc. increased its position in Royalty Pharma by 173.4% during the 1st quarter. Blue Trust Inc. now owns 689 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 437 shares during the period. Lloyd Advisory Services LLC. purchased a new position in Royalty Pharma during the 4th quarter valued at about $30,000. Private Trust Co. NA increased its position in Royalty Pharma by 52.9% during the 4th quarter. Private Trust Co. NA now owns 832 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 288 shares during the period. Finally, Smartleaf Asset Management LLC increased its position in Royalty Pharma by 868.1% during the 3rd quarter. Smartleaf Asset Management LLC now owns 881 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 790 shares during the period. Hedge funds and other institutional investors own 54.35% of the company’s stock.

About Royalty Pharma

(Get Free Report)

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.